Non-Invasive Imaging for Cording in Breast Cancer Patients
Completed · Not applicable
Conditions studied: Breast Cancer
In brief
To date, the scientific literature has yet to provide sufficient evidence regarding the pathophysiology of cording. The objective of this protocol is to evaluate the utility of non invasive vascular imaging for assessing the pathophysiology of cording in a small study cohort of patients who were treated for breast cancer. The hypothesis is that cording may have a vascular etiology
Key facts
- Study ID
- NCT01427166
- Run by
- Massachusetts General Hospital
- People needed
- 5
- Starts
- 2011-08-01
- Expected to finish
- 2012-08-01
- Last updated by the study team
- 2016-03-16
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Participants must be enrolled in Partners protocol # 2008P000540 "Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer"
- Confirmed case of cording by a medical provider (Physician, Nurse Practitioner, Physician Assistant)
- Participants must be at least 18 years of age
- Life expectancy of greater than 1 year.
- Ability to understand and the willingness to sign a written informed consent document.
- Willingness to comply with required follow up Perometer measurements and clinical visits.
You may not qualify if…
- Participants who are not enrolled or have been removed from Partners Protocol # 2008P000540 will be excluded from this trial.
- Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- History of prior surgery or radiation to the head, neck, upper limb, or trunk.
- Patients with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.